Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy.

ABSTRACT:

Background

The threshold of sufficient evidence for adoption of clinically- and genomically-guided precision medicine (PM) has been unclear.

Objective

To evaluate evidence thresholds for clinically guided PM versus genomically guided PM.

Methods

We develop an "evidence threshold criterion" (ETC), which is the time-weighted difference between expected value of perfect information and incremental net health benefit minus the cost of research, and use it as a measure of evidence threshold that is proportional to the upper bound of disutility to a risk-averse decision maker for adopting a new intervention under decision uncertainty. A larger (more negative) ETC value indicates that only decision makers with low risk aversion would adopt new intervention. We evaluated the

SUBMITTER: Guzauskas GF 

PROVIDER: S-EPMC6746330 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature